


Technology Advisory Committee A Interests Register

Topic: Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

Publication Date: 09/01/2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Joseph Sacco	Clinical expert	Indirect - financial	Dr Sacco declared the following interests in his capacity as:	10/09/2024	It was agreed Dr Sacco's declaration would not prevent him from providing expert advice to the committee.
			Chair of an IDMC for trial of an Immunocore agent against Hepatitis B		
			 a co-investigator on an international registry in uveal melanoma that has received funding from Immunocore. Funds from this grant support the infrastructure and sites. 		
			- translational lead on a clinical trial in setup that is funded by Immunocore (through EORTC)		
			 the chief investigator on a study funded by BMS 		
			co-Cl and translational lead on a study supported by AstraZeneca (through combinations alliance)		



			- is or has been a local PI on a number of studies with commercial sponsors: BMS, AZ, MSD, Immunocore, Replimune, Amgen, Qbiotics, Transgene.		
Rumana Hussain	Clinical expert	Indirect - financial	Immunocore sponsored the national oncology meeting for the past few years. Nothing in terms of personal sponsorship.	10/09/2024	It was agreed Ms Hussain's declaration would not her from providing expert advice to the committee.
Dr Paul Nathan	Clinical expert	Direct financial	Dr Nathan has received payment for advisory board membership and speaker's bureau for multiple pharmaceutical companies including Immunocore.	14/09/2021	It was agreed Dr Nathan's declaration would not prevent him from providing expert advice to the committee.
Dr Paul Nathan	Clinical expert	Direct financial	Dr Nathan has received payment for advisory board membership and speaker's bureau for multiple pharmaceutical companies including Immunocore.	04/07/2023	It was agreed Dr Nathan's declaration would not prevent him from providing expert advice to the committee.